Trial Profile
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 Jul 2020 According to an Arcutis Biotherapeutics media release, the Jiangsu Hengrui Medicine has completed this study in the mid-2019.
- 13 Jul 2020 Status changed from not yet recruiting to completed, according to an Arcutis Biotherapeutics media release.
- 24 Aug 2017 New trial record